Tag: lisocabtagene maraleucel

Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL

Bristol-Myers Squibb Announces Submission of Biologics License Application to the U.S. Food and Drug Administration (FDA) for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel)